• Explore /
  • Poster
  • / Development of bifunctional CRBN-SOS1 degraders for treatment of mutant KRAS cancers.

Development of bifunctional CRBN-SOS1 degraders for treatment of mutant KRAS cancers.

Abstract Poster

Authors

null

Kyle Begovich

Biotheryx, Inc, San Diego, CA

Kyle Begovich , Angela Schoolmeesters , Navin Rajapakse , Maneesh Kumar , Elena Martinez-Terroba , Arvind Shakya , Brandon Whitefield , Venkat Mali , Nataraj Pagadala , Akinori Okano , Shenlin Huang , Aparajita Hoskote Chourasia , Leah M. Fung

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Other Developmental Therapeutics

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3151)

DOI

10.1200/JCO.2023.41.16_suppl.3151

Abstract #

3151

Poster Bd #

349

Abstract Disclosures

Similar Posters

First Author: Biljana Bazdar-Vinovrski

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Synergistic effects of alpelisib (PI3K inhibitor) and ribociclib (CDK4/6 inhibitor) combination in preclinical colorectal cancer models.

Synergistic effects of alpelisib (PI3K inhibitor) and ribociclib (CDK4/6 inhibitor) combination in preclinical colorectal cancer models.

First Author: Razia Aslam

First Author: Ramaswamy Govindan

First Author: Christine Megerdichian Parseghian